Difference between revisions of "Team:Cardiff Wales/practisepage1"

 
(4 intermediate revisions by the same user not shown)
Line 95: Line 95:
 
   <div class="container">
 
   <div class="container">
 
   <div class="dropdown">
 
   <div class="dropdown">
−
     <button class="dropbtn">Human Practise</button>
+
     <button class="dropbtn">Human Practice</button>
 
     <div class="dropdown-content">
 
     <div class="dropdown-content">
 
       <a href="#">Link 1</a>
 
       <a href="#">Link 1</a>
Line 122: Line 122:
 
div.transbox {
 
div.transbox {
 
   margin: 0px;
 
   margin: 0px;
−
   background-color: #ffff33;
+
   background-color: #d9d9d9;
 
   border: 1px solid black;
 
   border: 1px solid black;
 
   opacity: 0.9;
 
   opacity: 0.9;
Line 139: Line 139:
 
<div class="background">
 
<div class="background">
 
   <div class="transbox">
 
   <div class="transbox">
−
     <p><h1 style="color:rgb(51, 153, 255);"><center>Cardiff iGEM team 2017 Project Brief</center></h1></p>
+
     <p><h1 style="color: #006600;"><center>Cardiff iGEM team 2017 Project Brief</center></h1></p>
 
   </div>
 
   </div>
 
</div>
 
</div>
Line 151: Line 151:
 
</section>
 
</section>
 
</center>
 
</center>
−
<article>
+
<div style="background-color:#b3ffff; height:400px;width:45%;float:left;">
−
<div class="clear"></div>
+
      <h3><center>The 2017 Cardiff-Wales project has dual aims.</center></h3>
−
<div class="column half_size" >
+
<p> Primarily we will develop tools for plant synthetic biology using the golden gate phytobricks standard. We will take previously characterized promotor elements that respond to a variety of environmental stimuli and move these into the phytobrick standard. These promotor elements will be used to generate TUs that drive reporter gene expression and will represent useful tools for future iGEM teams.</p>
−
      <h3><center>Creating a thyroid stimulating hormone antagonist by removing essential N-linked glycosylation groups</center></h3>
+
<p> Secondly we will use these phytobricks to express the composite TSHantag protein, which is an antagonist for Graves Disease, caused by hyperthyroidism. The TSHantag has not previously been used as a therapeutic agent so we will use the tobacco gene expression system to produce high levels of the protein, which will then be tested in a human <i>in vitro</i> system by collaborators at the Cardiff University Medical School.</p>
 +
<p>We have expertise using the tobacco expression system so will welcome collaborations with iGEM teams who wish to test the function of their proteins in plants!</p>
 
</div>
 
</div>
−
<p> The objective of this project was to take the native version of thyroid stimulating hormone (<abbr title="thyroid stimulating hormone">TSH</abbr>, AKA. Thyrotropin) which activates a cascade in the thyroid gland to produce thyroid hormones thyroxine (T4) and tri-iodotyrosine (T3).</p>
+
 
−
<p> By changing the amino acid sequence of the native TSH protein, we can disable the gland-activating effects of TSH, whilst still allowing TSH to bind to the gland. The engineered version still binds to the thyroid gland but does not activate it. Thus, it competitively inhibits the native TSH, and is potentially a therapeutic treatment for hyperthyroidism.</p>
+
<div style="background-color:#b3ffff; height:400px;width:45%;float:right;">
−
</article>
+
<h3><center>This promises to be an exciting year of iGEM research!</center><h3>
 +
<img src="https://static.igem.org/mediawiki/2017/f/f3/T-Cardiff_Wales-Gilson_Tobacco.jpg" width="100%" height="90%"/>
 +
</div>
 +
 
 +
 
 
<body background="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSUtIbKfCP6i2VeNWZv3MoMzvXxBOcAIEQOX_Dn-DKqnmO9dnl8srDIArc">
 
<body background="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSUtIbKfCP6i2VeNWZv3MoMzvXxBOcAIEQOX_Dn-DKqnmO9dnl8srDIArc">
 
</body>
 
</body>
 +
<footer>
 +
<center>
 +
<img src="https://pbs.twimg.com/profile_images/864443792421658624/X1nlXOkx_400x400.jpg" width="100" height="100"/>
 +
<img src="https://www.cpl.ie/Library/CPL/cpl.ie/About%20us/Company%20Logos/Merck-Millipore-Cpl-Jobs.jpg?width=457&height=457&ext=.jpg" width="100" height="100"/>
 +
<img src="https://www.jacksonimmuno.com/img/static-pages/Stratech-Logo.png" width="400" height="100"/>
 +
</center>
 +
</footer>

Latest revision as of 16:15, 1 July 2017

Project

Cardiff iGEM team 2017 Project Brief

The 2017 Cardiff-Wales project has dual aims.

Primarily we will develop tools for plant synthetic biology using the golden gate phytobricks standard. We will take previously characterized promotor elements that respond to a variety of environmental stimuli and move these into the phytobrick standard. These promotor elements will be used to generate TUs that drive reporter gene expression and will represent useful tools for future iGEM teams.

Secondly we will use these phytobricks to express the composite TSHantag protein, which is an antagonist for Graves Disease, caused by hyperthyroidism. The TSHantag has not previously been used as a therapeutic agent so we will use the tobacco gene expression system to produce high levels of the protein, which will then be tested in a human in vitro system by collaborators at the Cardiff University Medical School.

We have expertise using the tobacco expression system so will welcome collaborations with iGEM teams who wish to test the function of their proteins in plants!

This promises to be an exciting year of iGEM research!